Table 1. Clinical characteristics of the patients.
| Variables | n | % | |
|---|---|---|---|
| Staging* | |||
| IA | 15 | 15.5 | |
| IIA | 34 | 35.1 | |
| IIB | 32 | 33.0 | |
| IIIA | 5 | 5.1 | |
| IIIB | 11 | 11.3 | |
| HER2 | |||
| Negative | 62 | 62.0 | |
| + | 20 | 20.0 | |
| ++ | 6 | 6.0 | |
| +++ | 12 | 12.0 | |
| ER* | |||
| Negative | 18 | 18.2 | |
| Positive | 81 | 81.8 | |
| PR | |||
| Negative | 21 | 21.0 | |
| Positive | 79 | 79.0 | |
| Chemotherapy | |||
| No | 4 | 4.0 | |
| Yes | 96 | 96.0 | |
| Median | p.25–p.75 | ||
| Age | 56.0 | 49.0–68.0 | |
| Survivin | 1.6 | 0.008–23.6 | |
| Ki-67 (%) | 5.0 | 0.0–20.0 | |
HER2: human epidermal growth factor receptor 2; ER: estrogen receptor; PR: progesterone receptor
*
without information for some samples.